Identification of Th1-responsive leishmanial excretory-secretory antigens (LESAs)

Experimental Parasitology

Volumn 132, Issue 3, 2012, Pages 355-361

  Gour, Jalaj K ^a   Kumar, Vinod ^a   Singh, Nisha ^a   Bajpai, Surabhi ^a   Pandey, Haushila P ^a   Singh, Rakesh K ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Excretory secretory proteins; Leishmaniasis; Th1 response

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; PARASITE ANTIGEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIGEN DETECTION; ANTIGENIC MODULATION; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOMODULATION; IN VITRO STUDY; LEISHMANIA DONOVANI; LEISHMANIASIS; LYMPHOCYTE PROLIFERATION; MACROPHAGE ACTIVATION; MOLECULAR MODEL; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN DETERMINATION; TH1 CELL;

ANIMALS; ANTIGENS, PROTOZOAN; CELL LINE; CELL PROLIFERATION; CYTOKINES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; LEISHMANIA DONOVANI; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; MICE; MOLECULAR WEIGHT; NADPH OXIDASE; NITRIC OXIDE; SUPEROXIDE DISMUTASE; TH1 CELLS;

LEISHMANIA DONOVANI; PROTOZOA;

EID: 84867331125     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2012.04.022     Document Type: Article

References (45)

1. Ait-Oudhia K., Gazanion E., Oury B., Vergnes B., Sereno D. The fitness of antimony-resistant Leishmania parasites: lessons from the field. Trends Parasitol. 2011, 27:141-142.
2. Awasthi A., Mathur R.K., Saha B. Immune response to Leishmania infection. Indian J. Med. Res. 2004, 119:238-258.
3. Bacellar O., D'oliveira A., Jerônimo S., Carvalho E.M. IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. Cytokine 2000, 12:1228-1231.
4. Castellanos-Serra L.R., Fernandez-Patron C., Hardy E., Santana H., Huerta V. High yield elution of proteins from sodium dodecyl sulfate-polyacrylamide gels at the low-picomole level. Application to N-Terminal sequencing of a scarce protein and to in-solution biological activity analysis of on-gel renatured proteins. J. Protein Chem. 1997, 16:415-419.
5. Chenik M., Lakhal S., Ben Khalef N., Zribi L., Louzir H., Dellagi K. Approaches for the identification of potential excreted/secreted proteins of Leishmania major parasites. Parasitology 2006, 132:493-509.
6. Choudhury R., Das P., Bhaumik S.K., De T., Chakraborti T. In situ immunolocalization and stage-dependent expression of a secretory serine protease in Leishmania donovani and its role as a vaccine candidate. Clin. Vaccine Immunol. 2010, 17:660-667.
7. Cibrelus P., Precigout E., Sereno D., Carcy B., Lemesre J.L., Gorenflot. A secreted antigens of the amastigote and promastigote forms of Leishmania infantum inducing a humoral response in humans and dogs. Parasite 1999, 6:121-129.
8. Coler R.N., Goto Y., Bogatzki L., Raman V., Reed S.G. Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. Infect. Immun. 2007, 75:4648-4654.
9. De Trez C., Magez S., Akira S., Ryffel B., Carlier Y., Muraille E. INOS-producing inflammatory dendritic cells constitute the major infected cell type during the chronic Leishmania major infection phase of C57BL/6 resistant mice. PLoS Pathog. 2009, 5:e1000494.
10. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. 2004, 27:305-318.
11. Ding A.H., Nathan C.F., Stuehr D. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J. Immunol. 1988, 141:2407-2412.
12. El Ridi R., Tallima H., Mahana N., Dalton J.P. Innate immunogenicity and in vitro protective potential of Schistosoma mansoni lung schistosomula excretory-secretory candidate vaccine antigens. Microbes Infect. 2010, 12:700-709.
13. El-On J. Current status and perspectives of the immunotherapy of leishmaniasis. Isr. Med. Assoc. J. 2009, 11:623-628.
14. Fonseca S.G., Romao P.R., Figueiredo F., Morais R.H., Lima H.C., Ferreira S.H., Cunha F.Q. TNF-alpha mediates the induction of nitric oxide synthase in macrophages but not in neutrophils in experimental cutaneous leishmaniasis. Eur. J. Immunol. 2003, 33:2297-2306.
15. Garg R., Gupta S.K., Tripathi P., Naik S., Sundar S., Dube A. Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani. Clin. Exp. Immunol. 2005, 140:149-156.
16. Goto H., Prianti M.G. Immunoactivation and immunopathogeny during active visceral leishmaniasis. Rev. Inst. Med. Trop. Sao Paulo 2009, 51:241-246.
17. Holzmuller P., Cavaleyra M., Moreaux J., Kovacic R., Vincendeau P., Papierok G., Lemesre J.L. Lymphocytes of dogs immunised with purified excreted-secreted antigens of Leishmania infantum co-incubated with Leishmania infected macrophages produce IFN gamma resulting in nitric oxide-mediated amastigote apoptosis. Vet. Immunol. Immunopathol. 2005, 106:247-257.
18. Hsu A.C., Scott P. Leishmania mexicana infection induces impaired lymph node expansion and Th1 cell differentiation despite normal T cell proliferation. J. Immunol. 2007, 179:8200-8207.
19. Kamhawi S. Phlebotomine sand flies and Leishmania parasites: friends or foes?. Trends Parasitol. 2006, 22:439-445.
20. Kar S., Sharma G., Das P.K. Fucoidan cures infection with both antimony-susceptible and -resistant strains of Leishmania donovani through Th1 response and macrophage-derived oxidants. J. Antimicrob. Chemother. 2011, 66:618-625.
21. Kumar P., Pai K., Pandey H.P., Sundar S. NADH-oxidase, NADPH-oxidase and myeloperoxidase activity of visceral leishmaniasis patients. J. Med. Microbiol. 2002, 51:832-836.
22. Kumar V., Gour J.K., Bajpai S., Mishra M., Singh R.K. Detection of urinary antigens and their seroreactivity with serum of patients in Leishmania donovani infection. Asian Pac. J. Trop. Med. 2011, 4:367-370.
23. Kumari S., Samant M., Misra P., Khare P., Sisodia B., Shasany A.K., Dube A. Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1kDa offers long-lasting protection against experimental visceral leishmaniasis. Vaccine 2008, 26:5700-5711.
24. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
25. Laniado-Laborin R., Cabrales-Vergas M.N. Amphotericin B: Side effects and toxicity Revista Iberoamericana de Micología 2009, 26:223-227.
26. Lemesre J.L., Holzmuller P., Cavaleyra M., Goncalves R.B., Hottin G., Papierok G. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of L. infantum promastigotes. Vaccine 2005, 23:2825-2840.
27. Lowry O.H., Rosebrough N.J., Farr A.L., Randal R.J. Protein measurement with folin-phenol reagent. J. Biol. Chem. 1951, 193:265-275.
28. Mahapatra S.K., Chakraborty S.P., Roy S. In vitro time dependent nicotine-induced free radical generation and status of glutathione cycle in murine peritoneal macrophage. Al Ameen J. Med. Sci. 2010, 3:182-194.
29. Maue A.C., Waters W.R., Davis W.C., Palmer M.V., Minion F.C., Estes D.M. Analyais of immune response directed toward a recombinant early secretory antigenic filtrate protein 10 fusion protein in Mycobacterium bovis-infected cattle. Infect. Immun. 2005, 73:6659-6667.
30. Mehrani H., Mahmoodzadeh A. Immunological effects of Leishmania major secretory and excretory products on cutaneous leishmaniasis in BALB/c mice. Iranian J. Parasitol. 2007, 2:9-19.
31. Melby P.C., Yang J., Zhao W., Perez L.E., Cheng J. Leishmania donovani p36 (LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun. 2001, 69:4719-4725.
32. Mishra H.P., Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J. Biol. Chem. 1972, 247:3170-3175.
33. Moreira W., Leblanc E., Ouellette M. The role of reduced pterins in resistance to reactive oxygen and nitrogen intermediates in the protozoan parasite Leishmania. Free Radical Biol. Med. 2009, 46:367-375.
34. Mosmann T.R., Coffman R.L. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 1989, 7:145-173.
35. Murray H.W., Lu C.M., Mauze S., Freeman S., Moreira A.L., Kaplan G., Coffman R.L. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun. 2002, 70:6284-6293.
36. Murray H.W. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India. Future Microbiol. 2010, 5:1301-1313.
37. Nagill R., Kaur S. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis. Vaccine 2010, 28:4002-4012.
38. Rajasekariah G.H., Smithyman A.M., Gupta R.K., Martin S.K. The utility of exo antigens for detection of Leishmania infections. Mil. Med. 2007, 172:482-485.
39. Saha S., Mondal S., Banerjee A., Ghose J., Bhowmick S., Ali N. Immune responses in kala-azar. Indian J. Med. Res. 2006, 123:245-266.
40. Satti I.N., Osman H.Y., Daifalla N.S., Younis S.A., Khalil E.A., Zijlstra E.E., El, Hassan A.M., Ghalib H.W. Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers. Vaccine 2001, 19:2100-2106.
41. Singh R.K., Pandey H.P., Sundar S. Visceral leishmaniasis (Kala-azar): challenges ahead. Indian J. Med. Res. 2006, 123:331-344.
42. Singh S.P., Reddy D.C., Rai M., Sundar S. Serious under reporting of visceral leishmaniasis through passive case reporting in Bihar, India. Tropical Med. Int. Health 2006, 11:899-905.
43. Singh R., Kumar D., Ramesh V., Negi N.S., Singh S., Salotra P. Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis. J. Infect. Dis. 2006, 194:302-306.
44. Van Assche T., Deschacht M., da Luz R.A., Maes L., Cos P. Leishmania-macrophage interactions: insights into the redox biology. Free Radical Biol. Med. 2011, 51:337-351.
45. Zucca M., Savoia D. Current developments in the therapy of protozoan infections. Open Med. Chem. J. 2011, 5:4-10.